AstraZeneca's vaccine may cause an extremely rare blood clotting disorder, but its benefits vastly outweigh the risks for most people. It's highly effective in older adults and close to 100% effective in preventing severe COVID-19 and death from the coronavirus (SARS-CoV-2). Get a medical & scientific perspective on what the data really says about the Oxford-AstraZeneca vaccine. Learn how researchers discovered this very rare side effect ("vaccine-induced immune thrombotic thrombocytopenia"), how to put the risk in perspective (it's almost unimaginably tiny), and why the benefit-risk ratio remains so favourable.

#covid #covidvaccine #astrazenecavaccine #astrazeneca #bloodclot #cvst #cvt #data #vaccine #rct #science #medicine #research

CONTENTS
==========================
00:00 Intro: AstraZeneca vaccine likely causes extremely rare clotting disorder
00:28 Spoiler Alert: TL;DW Conclusion
01:10 AstraZeneca Vaccine effective & very safe: clinical trials
02:03 RCTs: What are they & why they're important
02:43 Limitation: RCTs can't detect extremely rare side effects
03:17 Rare side effect does NOT mean vaccine was rushed
03:49 How this rare side effect was discovered: Robust safety monitoring
04:13 Latest evidence on Vaccine-Induced Immune Thrombotic Thrombocytopenia (VITT)
05:32 How rare is rare? Imagining unimaginably small risks
07:09 Always must weigh benefits & risks
07:40 Risk of Death from COVID vs. risk of clot from AZ vaccine
08:10 Robust Benefit-risk analysis from Cambridge statisticians (Winton Centre)
10:12 COVID-19 causes way more clots than AZ vaccine
10:46 AZ Vaccine Benefits vastly outweigh risks for most people

REFERENCES
==========================
Amoozegar F et al. Hormonal contraceptives and cerebral venous thrombosis risk: a systematic review and meta-analysis. Front Neurol. 2015. doi.org/10.3389/fneur.2015.00007
Cines DB et al. SARS-CoV-2 Vaccine-Induced Immune Thrombotic Thrombocytopenia. N Engl J Med. 2021. doi.org/10.1056/NEJMe2106315
Coutinho JM et al. The incidence of cerebral venous thrombosis: a cross-sectional study. Stroke. 2012. doi.org/10.1161/STROKEAHA.112.671453
Devasagayam S et al. Cerebral Venous Sinus Thrombosis Incidence Is Higher Than Previously Thought: A Retrospective Population-Based Study. Stroke. 2016. doi.org/10.1161/STROKEAHA.116.013617
Greinacher A et al. Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination. N Engl J Med. 2021. doi.org/10.1056/NEJMoa2104840
Taquet M et al. Cerebral venous thrombosis: a retrospective cohort study of 513,284 confirmed COVID-19 cases and a comparison with 489,871 people receiving a COVID-19 mRNA vaccine. [unpublished pre-print]. 2021.
Schultz NH et al. Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination. N Engl J Med. 2021. doi.org/10.1056/NEJMoa2104882
Scully M et al. Pathologic Antibodies to Platelet Factor 4 after ChAdOx1 nCoV-19 Vaccination. N Engl J Med. 2021. doi.org/10.1056/NEJMoa2105385
Silvis SM et al. Cerebral venous thrombosis. Nat Rev Neurol. 2017. doi.org/10.1038/nrneurol.2017.104
Stegeman BH et al. Different combined oral contraceptives and the risk of venous thrombosis: systematic review and network meta-analysis. BMJ. 2013. doi.org/10.1136/bmj.f5298
Winton Centre. Communicating the potential benefits and harms of the Astra-Zeneca COVID-19 vaccine. 2021. [ Ссылка ]

свернуть